Altimmune, Inc. (NASDAQ: ALT) disclosed a direct purchase of company common stock by President and Chief Executive Officer Jerome Benedict Durso on March 6, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The filing shows Durso bought 20,000 shares at a weighted average price of $3.5395, with per-share prices in the transaction ranging from $3.5300 to $3.5500. The aggregate cost of the acquisition was $70,790. At the time of the transaction, the stock had slipped roughly 15 percent over the previous week and was trading near $3.54.
Following the purchase, Durso's direct holdings in Altimmune stand at 32,500 shares. Separately, analysis from InvestingPro indicates the stock appears to be trading above its Fair Value benchmark.
Financial results announced for the fourth quarter of 2025 showed Altimmune reporting an earnings per share (EPS) loss of $0.27, missing the forecasted loss of $0.25 and constituting an EPS surprise of -8 percent. Revenue for the quarter reached $26 million, which was substantially below the expected $625 million stated in the report.
Following the quarterly announcement and the interim data from Altimmune's Phase IIb IMPACT trial of pemvidutide in MASH, William Blair maintained a Market Perform rating on the stock. The trial demonstrated therapeutic activity but, according to the firm, did not provide clear clinical differentiation in a competitive market that includes treatments from Madrigal, Novo Nordisk, Boehringer Ingelheim, and Eli Lilly.
The purchase by the chief executive comes amid pronounced investor scrutiny after the earnings and revenue misses and ongoing competitive pressures in the metabolic and liver disease treatment space. The filing and the contemporaneous valuation assessment by InvestingPro are part of the recent developments surrounding Altimmune.
Readers interested in additional proprietary valuation context can access comprehensive Pro Research Reports that cover ALT alongside more than 1,400 U.S. equities, which the service promotes as offering in-depth analysis for investment decision-making.
Given the details in the filings and the company disclosures, market participants will likely note both the insider purchase and the recent operating results as part of their ongoing assessment of Altimmune's prospects.